• Home
  • Search Results
  • Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureus.

Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureus.

European journal of medicinal chemistry (2014-09-14)
Hui Wang, Yang Lu, Li Liu, Sung Won Kim, Jacob M Hooker, Joanna S Fowler, Peter J Tonge
ABSTRACT

The pharmacokinetics (PK) and pharmacodynamics (PD) of PT119, a potent Staphylococcus aureus enoyl-ACP reductase (saFabI) inhibitor with a Ki value of 0.01 nM and a residence time of 750 min on the enzyme target, has been evaluated in mice. PT119 was found to have promising antibacterial activity in two different S. aureus infection models: it caused a 3 log reduction in the CFU's in a mouse thigh muscle infection model and increased the survival rate from 0% to 50% in a mouse systemic infection model. PT119 was then radiolabeled with carbon-11 to evaluate its biodistribution and PK in both healthy and S. aureus infected mice using positron emission tomography (PET). The biodistribution of [11C]PT119 and/or its labeled metabolites did not differ significantly between the healthy group and the infected group, and PT119 was found to distribute equally between serum and tissue during the ∼1 h of analysis permitted by the carbon-11 half life. This approach provides important data for PK/PD modeling and is the first step in identifying radiotracers that can non-invasively image bacterial infection in vivo.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Boron tribromide solution, 1.0 M in methylene chloride
Sigma-Aldrich
Boron tribromide, ≥99.99%
Sigma-Aldrich
Boron tribromide, ReagentPlus®, ≥99%
Sigma-Aldrich
Boron tribromide, ReagentPlus®, 99.9%
Sigma-Aldrich
Boron tribromide solution, 1.0 M in hexanes
Sigma-Aldrich
Boron tribromide solution, 1.0 M in heptane